[go: up one dir, main page]

CA2404370A1 - Compositions a base de taxane et procedes d'utilisation - Google Patents

Compositions a base de taxane et procedes d'utilisation Download PDF

Info

Publication number
CA2404370A1
CA2404370A1 CA002404370A CA2404370A CA2404370A1 CA 2404370 A1 CA2404370 A1 CA 2404370A1 CA 002404370 A CA002404370 A CA 002404370A CA 2404370 A CA2404370 A CA 2404370A CA 2404370 A1 CA2404370 A1 CA 2404370A1
Authority
CA
Canada
Prior art keywords
composition
taxane
paclitaxel
compositions
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002404370A
Other languages
English (en)
Inventor
Kai Zhang
Gregory A. Smith
Jose C. Gutierrez-Roca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharmaceuticals Inc filed Critical Baker Cummins Pharmaceuticals Inc
Publication of CA2404370A1 publication Critical patent/CA2404370A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions à base de taxane et des procédés permettant d'utiliser ces compositions pour atteindre des concentrations sanguines cibles de taxane chez un mammifère, par exemple, pour traiter des maladies malignes et des maladies bénignes. Les compositions décrites dans cette invention présentent une stabilité à long terme et une sapidité globale. L'invention concerne également des procédés permettant d'utiliser ces compositions comme outils d'analyse dans des études pharmacocinétiques.
CA002404370A 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation Abandoned CA2404370A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19180200P 2000-03-24 2000-03-24
US60/191,802 2000-03-24
PCT/US2001/009382 WO2001072299A1 (fr) 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2404370A1 true CA2404370A1 (fr) 2001-10-04

Family

ID=22706985

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002404374A Abandoned CA2404374A1 (fr) 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane
CA002404370A Abandoned CA2404370A1 (fr) 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002404374A Abandoned CA2404374A1 (fr) 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane

Country Status (7)

Country Link
EP (2) EP1315484A1 (fr)
JP (2) JP2003528142A (fr)
KR (2) KR20030019327A (fr)
AR (2) AR027715A1 (fr)
AU (2) AU2001247739A1 (fr)
CA (2) CA2404374A1 (fr)
WO (2) WO2001072299A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466851C (fr) * 2001-11-26 2012-09-11 Supergen, Inc. Procede de preparation et d'utilisation d'huile de ricin polyoxyethylee dans des compositions pharmaceutiques
AU2002360816A1 (en) * 2001-12-28 2003-07-24 Ivax Research, Inc. Taxane based compositions and methods of use
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
DE602005025883D1 (de) * 2004-08-03 2011-02-24 Vital Health Sciences Pty Ltd Träger für die enterale verabreichung
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
AU2006212177A1 (en) * 2005-02-10 2006-08-17 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration
EP1690551A3 (fr) 2005-02-10 2006-10-18 Sindan Pharma Srl Purification d'un tenside par ultrafiltration
JP2008543789A (ja) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
WO2006133506A1 (fr) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd Charge comprenant un ou plusieurs dérivés de di- et/ou monophosphate d’agent de transfert d’électrons ou des complexes de ceux-ci
PT1931321T (pt) 2005-08-31 2019-05-14 Abraxis Bioscience Llc Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos
US8512761B2 (en) * 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
JP5868414B2 (ja) * 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド タキソイドの医薬組成物
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2907726A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs selectifs de la kinase aurora a
CN114712308A (zh) 2015-12-09 2022-07-08 磷肌酸有限公司 药物制剂
US20190330260A1 (en) 2016-12-21 2019-10-31 Avecho Biotechnology Limited Process
CN110585189B (zh) * 2019-09-05 2022-12-30 广东艾时代生物科技有限责任公司 三尖杉宁碱在制备治疗疟疾药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
CN1225262A (zh) * 1998-12-09 1999-08-11 延边香料研究所 一种含有紫杉醇的抗癌药物
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
EP1315484A1 (fr) 2003-06-04
CA2404374A1 (fr) 2001-10-04
AR027715A1 (es) 2003-04-09
JP2003528142A (ja) 2003-09-24
AR027714A1 (es) 2003-04-09
JP2003528141A (ja) 2003-09-24
WO2001072300A1 (fr) 2001-10-04
EP1408956A1 (fr) 2004-04-21
KR20030019327A (ko) 2003-03-06
KR20030019328A (ko) 2003-03-06
AU2001247739A1 (en) 2001-10-08
WO2001072299A1 (fr) 2001-10-04
AU2001247726A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20040127551A1 (en) Taxane-based compositions and methods of use
CA2404370A1 (fr) Compositions a base de taxane et procedes d'utilisation
US6964946B1 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
EP1658050B1 (fr) Forme galenique huileuse auto-nanoemulsifiante pour l'administration de medicaments difficilement hydrosolubles
US6730698B2 (en) Method and compositions for administering taxanes orally to human patients
CA2471572A1 (fr) Compositions a base de taxane et procedes d'utilisation
RU2205005C2 (ru) Способ и композиции для перорального введения таксанов пациентам
AU1104201A (en) Method and compositions for administering taxanes orally to human patients
WO2004091506A2 (fr) Compositions a base de taxane et procedes d'utilisation
EP1479382A1 (fr) Compositions pharmaceutiques orales contenant des taxanes et méthodes de traitement dans lesquelles lesdites compositions sont utilisées
RU2236226C2 (ru) Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
HK1071081A (en) Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
AU784159B2 (en) Method and compositions for administering taxanes orally to human patients
HK1047028A1 (zh) 含有紫杉烷的口服藥物組合物以及使用其的治療方法
HK1074006A (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs

Legal Events

Date Code Title Description
FZDE Dead